Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
COMMETS- Combination MCI Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 80
- Registration Number
- NCT06072963
- Locations
- 🇮🇱
Joseph Sagol Neuroscience center, Sheba Medical Center, Ramat Gan, Israel
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2700
- Registration Number
- NCT06065540
- Locations
- 🇷🇸
CHC Zvezdara, Clinical department for endocrinology, Belgrade, Serbia
🇪🇸Hospital General de Segovia, Segovia, Spain
🇹🇷Tekirdag Namık Kemal UTF, Tekirdag, Turkey
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1576
- Registration Number
- NCT06045221
- Locations
- 🇲🇽
Caimed Investigacion En Salud S.A. de C.V., Mexico City, Distrito Federal, Mexico
🇺🇸Absolute Clinical Research, Phoenix, Arizona, United States
🇺🇸San Fernando Valley Health Institute, Canoga Park, California, United States
DIALYSIS-TIR Study
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 157
- Registration Number
- NCT06042153
- Locations
- 🇺🇸
Davita UT Southwestern - Oak Cliff, Dallas, Texas, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸DaVita UT Southwestern - East Dallas, Dallas, Texas, United States
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 162
- Registration Number
- NCT06041217
- Locations
- 🇨🇳
Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳Fujian Medical University Union Hospital-Endocrinology, Fuzhou, Fujian, China
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Rigmor Højland Jensen
- Target Recruit Count
- 50
- Registration Number
- NCT06027567
- Locations
- 🇩🇰
Danish Headache Center, Department of Neurology, Rigshospitalet, Glostrup, Denmark
🇩🇰Headache clinic, Department of Neurology, Odense University Hospital, Odense, Denmark
Semaglutide Therapy for Alcohol Reduction (STAR)
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 52
- Registration Number
- NCT06015893
- Locations
- 🇺🇸
National Institute on Drug Abuse, Baltimore, Maryland, United States
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 120
- Registration Number
- NCT06005012
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 121
- Registration Number
- NCT05996874
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 300
- Registration Number
- NCT05996848
- Locations
- 🇨🇳
Suzhou Municipal Hospital, Suzhou, Jiangsu, China
🇨🇳Tongren Hospital Shanghai Jiao Tong Univ. School of Medicine, Shanghai, Shanghai, China
🇨🇳Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.